Asparaginase Toxicities in ALL - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Asparaginase Toxicities in ALL

Rapid Identification, Management, and Patient/Family Partnerships to Improve Outcomes

Not a member of My prIME? Join now for instant access.

Get the latest updates on current and emerging asparaginase therapies in pediatric ALL with downloadable slides from our satellite symposium. A variety of topics are covered, including mechanism of action and pharmacokinetics, monitoring and management of asparaginase toxicities, and communication approaches specific to pediatric patients and their families.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Sep 17, 2018

Expiration Date

Sep 17, 2019

Featured Expert

  • Katie Gettinger, MSN, RN, CPNP-PC, St Louis Children’s Hospital, St Louis, Missouri, United States

Featured Topic

Asparaginase Review

Featured Experts

  • Anna Lefebvre, MSN, RN, CPNP, CPON, Dana Farber/ Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States
  • Joan Ronan, MSN, RN, CPNP, CPON, Dana Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States

Featured Topic

Identification and management of asparaginase toxicities

Featured Experts

  • Belinda Mandrell, PhD, RN, St Jude Children’s Research Hospital, Memphis, Tennessee, United States

Featured Topic

prIME Points™

This educational activity is designed to meet the needs of registered nurses and advanced practice registered nurses who provide care for pediatric patients with acute lymphoblastic leukemia (ALL).

  • Discuss current and emerging asparaginase therapies for pediatric patients, including mechanism of action, structure, bacterial source, and pharmacokinetics
  • Implement clinical nursing approaches for the monitoring and management of asparaginase toxicities for pediatric patients with ALL
  • Describe best practices in patient/family education and communication to improve outcomes for pediatric patients with ALL

This educational activity is supported by a grant from Shire.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is jointly provided by prIME Oncology and Postgraduate Institute for Medicine.

Disclosure Information

Disclosure of Relevant Financial Relationships

Postgraduate Institute of Medicine (PIM) and prIME Oncology assess relevant financial relationships with their instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by PIM and prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. PIM and prIME Oncology are committed to providing their learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Katie Gettinger, RN, MSN, CPNP-PC, has disclosed no relevant financial relationships. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Anna Lefebvre, MSN, RN, CPNP, CPON, has disclosed no relevant financial relationships. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Belinda Mandrell, PhD, RN, CPNP, has disclosed no relevant financial relationships. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Joan Ronan MSN, RN, CPNP, CPON, has disclosed no relevant financial relationships. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

The PIM planners and managers have nothing to disclose.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.